Athlete’s Foot Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Feb. 9, 2012 - PRLog -- GlobalData analysis shows that the global athlete’s foot therapeutics market stood at a value of $490.0m in 2006 and grew at a compound annual growth rate (CAGR) of 3.4%, to reach $580.5m in 2011.

GlobalData forecasts that the global athlete’s foot therapeutics market will grow at a CAGR of 3.0% over the next eight years to reach a value of $735.4m by 2019.

This slow growth can be attributed to the prominence of generics in the market. The current market is well served by generic classes such as azoles, allylamines and benzylamines. The only non-generic drug for athlete’s foot, Ertaczo (sertaconazole), can be found in the azoles class. This will become generic in May 2014 in the US.

In addition to this, the slow growth rate can be attributed to the reluctance of athlete’s foot patients to visit doctors for treatment, because athlete’s foot is not a serious infection and can be treated with over-thecounter (OTC) drugs in the initial stages.

Furthermore, slow growth is due to the weak product pipeline for athlete’s foot therapeutics. There are no first-in-class (FIC) molecules in the late stage of development. In Phase III, there are three product extensions, which, upon their launch, are not expected to create an impact in the market during the forecast period.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....


GlobalData’s analysis has found that current competition in the athlete’s foot therapeutics market is strong. The current market landscape has many marketed products that fall under the following classes: azoles, allylamines and benzylamines, and a number of others such as anti-fungals ciclopirox and griseofulvin. Drugs from these classes are relatively successful at meeting the therapeutic requirements of the market and have good efficacy and safety profiles. In addition, these drugs are available in different dosage forms and have high patient compliance rates. All of the products are able to cure athlete’s foot infections in most cases. As the current treatment options offer high efficacy and safety standards and successfully meet market demands, unmet need in the athlete’s foot therapeutics market is low.

Unmet need exists in cases of resistant athlete’s foot infections. These cases require FIC anti-fungals that can treat resistant athlete’s foot infections that cannot be treated with available therapies. However, unmet need is low in the athlete’s foot therapeutics market.

The current athlete’s foot therapeutics market is highly competitive, with more than 10 marketed products. The market is dominated by generics.

GlobalData, the industry analysis specialist, has released its new report, “Athlete’s Foot Therapeutics – Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global athlete’s foot therapeutics market. The report identifies the key trends shaping and driving the global athlete’s foot therapeutics market and provides insight into the competitive landscape and the emerging companies expected to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insight into pipeline products within the global athlete’s foot therapeutics market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Athl...


Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.